CTOs on the Move

AIkido Pharma

www.aikidopharma.com

 
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

AIkido Pharma raised $75M on 02/17/2021

Similar Companies

CoMentis

CoMentis is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Creative Biogene.Inc

Creative Biogene.Inc is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iBio

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio`s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It`s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people`s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world`s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

STIMIT

STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.